Sick of SEC and SAC? Here's a new thread that brings us back
to what investing is all about.
With its leading drug candidates for the treatment of brain
cancer and breast cancer nearing the third and final phase of
clinical trials, and with six more new drugs in the pipeline,
Celldex Therapeutics Inc.
is up 59% since January, and 145% over the last 12 months.
As of April 1, 2013 the SEC-weary SAC Capital Advisors founder
Steve Cohen increased his Celldex Therapeutics (
) position by 45.61%, putting his current shares at 3,931,355.
The current price is $11.13, with a 0% change from average.
The company has a market cap of $897.07 million. The P/B ratio is
7.3, and the P/S ratio is 57.4713.
Here's a detailed analysis of Celldex Therapeutics Inc.
Cohen's history with the stock shows and average cost of $5 per
share with a 123% gain since he bought in first quarter 2012.
His holding history:
Celldex Therapeutics, Inc. is a biopharmaceutical company focused
on the development of immunotherapy technologies and drugs for
the treatment of cancer and other difficult-to-treat diseases.
The company calls itself "the first antibody-based combination
immunotherapy company." With a product pipeline of eight
cancer-fighting drug candidates in development, Celldex features
a "Precision Targeted Immunotherapy Platform," a portfolio of
antibodies, antibody-targeted vaccines and immunomodulators used
in optimal combinations to create new and unique disease-specific
drug candidates. Its lead drug candidate, known as CDX-110,
targets a tumor-specific molecule, and is preparing to enter a
Phase 3 clinical trial for one of the most aggressive forms of
brain cancer. Drug candidate CDX-011 is currently undergoing
evaluation in a Phase 2b clinical trial in advanced breast
Last month Celldex Therapeutics, Inc. reported a net loss of
$16.8 million, or $0.27 per share, for the fourth quarter of 2012
compared to net loss of $12.7 million, or $0.29 per share, for
the fourth quarter of 2011. For the twelve months ended Dec. 31,
2012, Celldex reported a net loss of $59.1 million, or $1.02 per
share, compared to a net loss of $44.8 million, or $1.13 per
share, for the twelve months ended Dec. 31, 2011. Celldex
Therapeutics reported cash, cash equivalents and marketable
securities of $84 million as of Dec. 31, 2012. Following recent
financings, as of Feb. 28, 2013, Celldex had cash, cash
equivalents and marketable securities of approximately $189
Celldex Therapeutics CEO Anthony Marucci, said, "Celldex ended
2012 reporting positive data from four clinical programs at major
medical meetings, including final results from our Phase 2b study
of CDX-011 in metastatic breast cancer...Importantly, we begin
2013 well-financed with a current cash position that will support
operations and clinical development through 2015. To that end, in
addition to the CDX-011 accelerated approval study, we will also
initiate new clinical studies and expansion studies for four
other Celldex programs in 2013. We expect data from three
clinical studies by year end..."
As of April 1, 2013, SAC Capital's portfolio shows 1585 stocks at
a total value of $20.3 billion, and a quarter-over-quarter
turnover of 42%.
's top buys, sells, and holdings:
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to